Blair William & CO Editas Medicine, Inc. Transaction History

Blair William & CO

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$9.99 - $21.35 $193,336 - $413,186	-19,353 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$14.08 - $27.63 $64,416 - $126,407	4,575 Added 30.96%	19,353 $368,000
Q4 2021 Feb 14, 2022	BUY	$26.55 - $40.57 $47,869 - $73,147	1,803 Added 13.9%	14,778 $392,000
Q3 2021 Nov 12, 2021	SELL	$39.27 - $72.94 $1,178 - $2,188	-30 Reduced 0.23%	12,975 $533,000
Q2 2021 Aug 12, 2021	SELL	$31.29 - $56.64 $1,408 - $2,548	-45 Reduced 0.34%	13,005 $737,000
Q1 2021 May 13, 2021	BUY	$39.71 - $90.58 $53,608 - $122,283	1,350 Added 11.54%	13,050 $548,000
Q3 2020 Nov 06, 2020	BUY	$28.06 - $37.16 $25,254 - $33,444	900 Added 8.33%	11,700 $328,000
Q2 2020 Aug 12, 2020	BUY	$18.5 - $34.34 $2,775 - $5,151	150 Added 1.41%	10,800 $319,000
Q1 2020 May 11, 2020	SELL	$14.88 - $32.78 $8,928 - $19,668	-600 Reduced 5.33%	10,650 $211,000
Q3 2019 Nov 12, 2019	SELL	$22.49 - $26.81 $73,834 - $88,017	-3,283 Reduced 22.59%	11,250 $256,000
Q1 2019 May 14, 2019	SELL	$19.43 - $26.41 $18,225 - $24,772	-938 Reduced 6.06%	14,533 $355,000
Q4 2018 Feb 14, 2019	BUY	$18.19 - $31.79 $39,490 - $69,016	2,171 Added 16.32%	15,471 $352,000
Q3 2018 Nov 13, 2018	BUY	$27.65 - $38.39 $47,005 - $65,263	1,700 Added 14.66%	13,300 $423,000
Q2 2018 Aug 13, 2018	BUY	$31.4 - $41.01 $364,240 - $475,716	11,600 New	11,600 $416,000

247

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $168M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

Stay updated on Blair William & CO with notifications on news.